Escitalopram in clinical practice: Results of an open-label trial in outpatients with depression in a naturalistic setting in Germany

Pharmacopsychiatry

Volumn 40, Issue 2, 2007, Pages 53-57

  Moller H J ^a   Langer, S ^b   Schmauss M ^c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Lundbeck GmbH   (Germany)

^c Bezirkskrankenhaus Augsburg   (Germany)

Author keywords

Antidepressants; Citalopram; Community; Escitalopram; Major depressive disorder; Naturalistic; SSRI

Indexed keywords

ESCITALOPRAM;

ADULT; AGED; ANOREXIA; ANXIETY; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG SAFETY; ERECTILE DYSFUNCTION; FATIGUE; FEMALE; GERMANY; HEADACHE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTPATIENT CARE; PRIORITY JOURNAL; RATING SCALE; SIDE EFFECT; SLEEP DISORDER; SUICIDAL IDEATION; SUICIDE ATTEMPT; SWEATING; TREATMENT OUTCOME; TREMOR; VERTIGO; VOMITING;

ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BEHAVIOR THERAPY; CITALOPRAM; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; PHYTOTHERAPY; SOCIOECONOMIC FACTORS;

EID: 34247882655     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-970142     Document Type: Article

References (18)

1. Bech P, Andersen HF, Wade A: Effective dose of escitalopram in moderate versus severe DSM-IV major depression. Pharmacopsychiatry 2006; 39: 128-134
2. Boulenger JP, Huusom AKT, Florea I, Bækdal T, Sarchiapone M: A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr Med Res Opin 2006; 22: 1331-1341
3. Burke WJ, Gergel I, Bose A: Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002; 63: 331-336
4. Chen F, Larsen MB, Sánchez C, Wiborg O: The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol 2005; 15: 193-198
5. Colonna L, Reines EH, Andersen HF: A randomized,double-blind, 24-week study of escitalopram (10 mg/day)versus citalopram (20 mg/ day)in primary care patients with major depressive patients with major depressive disorder. Curr Med Res Opin 2005; 21: 1659-1668
6. Fachinformation zu CIPRALEX® 10 mg und CIPRALEX® 20 mg Filmtabletten. Lundbeck GmbH, Januar 2004
7. Guy W: ECDEU Assessment Manual for Psychopharmacology, revised. US Dept Health, Education, and Welfare publication (ADM) 76-338. 1976. Rockville, MD, National Institute of Mental Health
8. Kennedy SH, Andersen HF, Lam RW: Efficacy of escitalopram in the treatment of major depressive disorder: a meta-analysis versus selective serotonin reuptake inhibitors and venlafaxine XR. J Psychiatry Neuroscience 2006; 31: 122-131
9. Lam RW, Andersen HF: The influence of baseline severity on efficacy of escitalopram and citalopram in the treatment of major depressive disorder: an extended analysis. Pharmacopsychiatry. 2006; 39: 180-184
10. Lepola UM, Loft H, Reines EH: Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003; 18: 211-217
11. Linden M, Ludewig K, Munz T, Dierkes W: Dosage finding and outcome of venlafaxine treatment in psychiatric outpatients and inpatients: Results of a drug utilization observation study. Pharmacopsychiatry 2003; 36: 197-205
12. Moore N, Verdoux H, Fantino B: Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005; 20: 131-137
13. Möller HJ, Schnitker J: Einsatz einer modifizierten MADRS bei depressiven Patienten in einer prospektiven Kohortenstudie. Der Nervenarzt 2006; 77 (Suppl 2): S172-S173
14. Pedersen AG: Escitalopram and suicidally in adult depression and anxiety. Int Clin Psychopharmacol 2005; 20: 139-143
15. Rush AJ, Bose A: Escitalopram in clinical practice: Results of an open-label trial in a naturalistic setting. Depress Anxiety 2005; 21: 26-32
16. Sánchez C, Bøgesø K, Ebert B, Heldbo Reines E et al: Escitalopram versus Citalopram: the surprising role of the R-enantiomer. Psychopharmacology 2004; 174: 163-176
17. Wade AG, Lemming O, Hedegaard K: Escitalopram 10 mg/day is effective and well-tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002; 17: 95-102
18. Zimmerman M, Mattia JI, Posternak MA: Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? Am J Psychiatry 2002; 159: 469-473